PDS Biotechnology (PDSB)
(Delayed Data from NSDQ)
$3.20 USD
-0.01 (-0.31%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.19 -0.01 (-0.31%) 7:06 PM ET
2-Buy of 5 2
D Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
PDSB 3.20 -0.01(-0.31%)
Will PDSB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PDSB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PDSB
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
PDSB: What are Zacks experts saying now?
Zacks Private Portfolio Services
PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study
PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
Other News for PDSB
PDS Biotechnology (PDSB) Receives a Buy from Noble Financial
Buy Rating Justified: PDS Biotechnology’s Versamune HPV Shows Promise in Phase 2 Trials
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
PDS Biotech Advances with Promising Versamune® HPV Trial Results
PDS Biotechnology announces updates data from VERSATILE-002 trial